CoChat

Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland

Open access
Haase, Christiane Lundegaard, Serratore Achenbach, Maria Giovanna, Lucrezi, Gianluca, Jeswani, Nikita, Maurer, Susanne, Egermann, Ulrich · 2021 · Obesity Facts

The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.

Abstract

Introduction: Data from randomized controlled trials show that liraglutide 3.0 mg, in combination with diet and exercise, is associated with greater weight loss than diet and exercise alone in patients with obesity. In practice, the utilization of weight loss drugs is influenced by various factors, including the cost of treatment. We conducted a retrospective, observational study to assess the effectiveness of liraglutide 3.0 mg and patients’ persistence on treatment, in a real-world setting. Methods: Data were extracted from de-identified electronic medical records from an obesity management clinic in Switzerland. Changes in body weight and blood pressure were evaluated in the full cohort (N = 277, 19% of whom had undergone bariatric surgery) and subgroups who were persistent on liraglutide 3.0 mg for at least 4 months (n = 236), 7 months (n = 159), or 12 months (n = 71). Results: Median persistence on liraglutide was 6.8 months. Median maximum dose received was 1.5 mg, and 13.7% of patients reached the maintenance dose of 3.0 mg. Mean 7-month weight change from baseline in the full cohort was −4.1 kg (95% confidence interval: −5.0, −3.2; p < 0.001; −4.2%). Weight change was −4.4 kg (−4.7%) in the ≥4-month persistence subgroup at 4 months, −5.1 kg (−5.3%) in the ≥7-month persistence subgroup at 7 months, and −7.5 kg (−7.1%) in the ≥12-month persistence subgroup at 12 months (all p < 0.001). In the full cohort, 40% and 14% of patients lost ≥5% and >10% of body weight at 7 months, respectively. Weight loss did not differ significantly according to history of bariatric surgery (p = 0.94). Diastolic blood pressure decreased (from 87.0 to 83.9 mm Hg at 7 months; p = 0.018), with no significant changes in systolic blood pressure. Approximately two-thirds of patients did not have health insurance that could cover the cost of liraglutide. Conclusion: In a real-world setting with low insurance coverage and with most patients not reaching the recommended maintenance dose of 3.0 mg, the use of liraglutide, in combination with diet and exercise, was associated with clinically meaningful weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000518325

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 44

Metadata

Authors
Haase, C. L., Serratore Achenbach, M. G., Lucrezi, G., Jeswani, N., Maurer, S., & Egermann, U.
Affiliations
  • Novo Nordisk (Denmark) (DK)
  • IQVIA (United Kingdom) (GB)
Venue
Obesity Facts
Publisher
S. Karger AG
Published
2021
Volume
14
Issue
5
Pages
568-576
ISSN
  • 1662-4025 (ISSN-L)
  • 1662-4033
OpenAlex
W3193387990
Cited by
41
References
21
Citations by year
2026: 4 · 2025: 8 · 2024: 16 · 2023: 8 · 2022: 5
FWCI
4.23
Type
journal article
Language
en
Open access
Licence
Locations
  • Obesity Facts (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
liraglutide, obesity, weight loss, treatment persistence, dose escalation, bariatric surgery, blood pressure, health insurance coverage, cost barriers, real-world effectiveness, GLP-1 receptor agonists, Switzerland, diastolic blood pressure reduction
MeSH terms
Liraglutide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Retrospective Studies, Switzerland, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland. https://app.cochat.ai/papers/10.1159/000518325
The paper
Haase, C. L., Serratore Achenbach, M. G., Lucrezi, G., Jeswani, N., Maurer, S., & Egermann, U. (2021). Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland. Obesity Facts. https://doi.org/10.1159/000518325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.